Hypertrophic Cardiomyopathy Market Poised for Growth Through 2036
Demand for hypertrophic cardiomyopathy (HCM) treatments is expected to rise, despite current therapeutic limitations, according to new market research. Targeted therapies offer potential for change.
The global market for hypertrophic cardiomyopathy (HCM) treatments is projected for significant growth through 2036, according to a new market analysis by DelveInsight. HCM, the most common inherited cardiac disorder, is a major cause of heart failure and sudden cardiac death, particularly among young adults.
The research covers the United States, Japan, and the EU4 countries plus the UK. While exact market values are not specified in the release, the analysis indicates substantial market expansion anticipated in the coming years. Currently, the therapeutic landscape for HCM is relatively limited, with only a few disease-specific targeted therapies available. Mavacamten (CAMZYOS), a cardiac myosin inhibitor, was the first approved for symptomatic obstructive HCM. Recently, aficamten (MYQORZO) gained approval as a second cardiac myosin inhibitor for obstructive HCM and is viewed as a significant competitor to mavacamten.
Traditionally, HCM management has focused on symptom control and complication prevention using medications like beta-blockers and calcium channel blockers. However, newer therapies are designed to address the underlying mechanisms of the disease, such as excessive muscle contraction, potentially slowing or reversing disease-related changes over time.
The market analysis highlights significant unmet needs in HCM, particularly for non-obstructive HCM (non-oHCM), which faces limited targeted treatment options and persistent symptoms. A robust pipeline indicates growing investment from pharmaceutical and biotechnology firms like Lexicon Pharmaceuticals, Imbria Pharmaceuticals, and Edgewise Therapeutics in novel cardiac and metabolic therapies, suggesting a future with broader and more effective treatment possibilities.
The report, published in 2021 and projecting through 2036, focuses on market growth, epidemiology, and treatment evolution. Males are more frequently affected by HCM than females, and case numbers in the US are expected to increase by 2036.